Clinical Trial: Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Sponsor and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.
Contact: Christine McIsaac, RN
Melissa Alsina, MD H. Lee Moffitt Cancer Center and Research Institute